NASDAQ:DMTK DermTech (DMTK) Stock Price, News & Analysis $0.07 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.06▼$0.0750-Day Range$0.05▼$0.4252-Week Range$0.09▼$3.90Volume55,775 shsAverage Volume1.07 million shsMarket Capitalization$2.31 millionP/E RatioN/ADividend YieldN/APrice Target$2.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get DermTech alerts: Email Address DermTech MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside3,501.0% Upside$2.38 Price TargetShort InterestHealthy9.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.12) to ($2.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.45 out of 5 stars 3.0 Analyst's Opinion Consensus RatingDermTech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageDermTech has received no research coverage in the past 90 days.Read more about DermTech's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted9.50% of the float of DermTech has been sold short.Short Interest Ratio / Days to CoverDermTech has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DermTech has recently decreased by 10.12%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDermTech does not currently pay a dividend.Dividend GrowthDermTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DMTK. Previous Next 0.6 News and Social Media Coverage Search Interest3 people have searched for DMTK on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DermTech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of DermTech is held by insiders.Percentage Held by InstitutionsOnly 20.45% of the stock of DermTech is held by institutions.Read more about DermTech's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for DermTech are expected to grow in the coming year, from ($2.12) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DermTech is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DermTech is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermTech has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about DermTech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About DermTech Stock (NASDAQ:DMTK)DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.Read More DMTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DMTK Stock News HeadlinesJune 24, 2024 | investorplace.comWhy Is DermTech (DMTK) Stock Down 26% Today?June 18, 2024 | businesswire.comDermTech Files for Voluntary Chapter 11 ProtectionJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | investorplace.comDMTK Stock Earnings: DermTech Misses EPS, Misses Revenue for Q1 2024May 14, 2024 | msn.comDermTech GAAP EPS of -$0.58, revenue of $3.85MMay 14, 2024 | finance.yahoo.comDermTech Reports First-Quarter 2024 Financial ResultsApril 20, 2024 | investing.comDermTech stock downgraded by BTIG amid strategic reviewApril 19, 2024 | msn.comBTIG Downgrades DermTech (DMTK)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 19, 2024 | markets.businessinsider.comWhat Analysts Are Saying About DermTech StockApril 18, 2024 | marketwatch.comDermTech to Slash 56% of Workforce, Explore OptionsApril 18, 2024 | msn.comDermTech exploring strategic alternatives, cutting 56% of staffApril 18, 2024 | businesswire.comDermTech to Explore Strategic Alternatives and Implement Restructuring PlanApril 17, 2024 | finance.yahoo.comDermTech, Inc. (DMTK)March 8, 2024 | businesswire.comDermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative DermatologyMarch 7, 2024 | investing.comStephens cuts DermTech stock target to $1.50, keeps Equal Weight ratingMarch 2, 2024 | finance.yahoo.comDermTech, Inc. (NASDAQ:DMTK) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | benzinga.comRecap: DermTech Q4 EarningsSee More Headlines Receive DMTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:DMTK CUSIPN/A CIK1651944 Webwww.dermtech.com Phone(858) 450-4222FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Target$2.38 High Stock Price Target$5.00 Low Stock Price Target$0.63 Potential Upside/Downside+3,295.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,890,000.00 Net Margins-572.19% Pretax Margin-572.19% Return on Equity-138.79% Return on Assets-68.96% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.46 Sales & Book Value Annual Sales$15.66 million Price / Sales0.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book0.04Miscellaneous Outstanding Shares34,963,000Free Float33,180,000Market Cap$2.45 million OptionableOptionable Beta2.48 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Bret Christensen (Age 53)President, CEO & Director Comp: $973.97kMr. Kevin Sun M.B.A. (Age 46)CFO, Treasurer & Secretary Comp: $600.35kMr. Ray Akhavan Esq. (Age 55)J.D., General Counsel Comp: $555.93kMr. William W. ZondlerChief Information OfficerMr. Steve E. KunszaboSenior Director of Investor RelationsMs. Jennifer EilembergChief Compliance OfficerDr. Burkhard Jansen M.D. (Age 58)Chief Medical Affairs Officer Comp: $419.8kDr. Loren Clarke M.D.Chief Medical OfficerDr. Steven Stone Ph.D.Senior Vice President of Research & DevelopmentMr. Mark Aguillard (Age 51)Chief Commercial Officer More ExecutivesKey CompetitorsBioNexus Gene LabNASDAQ:BGLCOpGenNASDAQ:OPGNAclarionNASDAQ:ACONFresh2 GroupNASDAQ:FRESInvitaeNYSE:NVTAView All CompetitorsInsiders & InstitutionsTexas Capital Bank Wealth Management Services IncBought 80,000 shares on 5/13/2024Ownership: 0.578%Kevin M SunSold 447 sharesTotal: $648.15 ($1.45/share)Claudia IbarraSold 331 sharesTotal: $479.95 ($1.45/share)Kevin M SunSold 4,979 sharesTotal: $7,617.87 ($1.53/share)Claudia IbarraSold 3,911 sharesTotal: $5,983.83 ($1.53/share)View All Insider TransactionsView All Institutional Transactions DMTK Stock Analysis - Frequently Asked Questions How have DMTK shares performed this year? DermTech's stock was trading at $1.75 at the beginning of the year. Since then, DMTK stock has decreased by 96.2% and is now trading at $0.0660. View the best growth stocks for 2024 here. How were DermTech's earnings last quarter? DermTech, Inc. (NASDAQ:DMTK) announced its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.58) earnings per share (EPS) for the quarter. The company had revenue of $3.85 million for the quarter. DermTech had a negative net margin of 572.19% and a negative trailing twelve-month return on equity of 138.79%. How do I buy shares of DermTech? Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DermTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX) and Valero Energy (VLO). This page (NASDAQ:DMTK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DermTech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DermTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
